Canopy Growth Corporation's (NYSE: CGC) (TSX: WEED) subsidiary, Canopy Growth Germany GmbH announced on Wednesday that the company is changing from Spectrum Therapeutics to Canopy Medical in the German market.

Why It Matters

The move will align the company's medical business with the corporate Canopy Growth brand.

Moreover, this alignment further reinforces Canopy Growth's commitment to long-term growth within the German medical cannabis market and unwavering commitment to German medical cannabis patients, the Canadian cannabis giant said in a press release.

Tara Rozalowsky, chief growth officer and president of international markets at Canopy Growth said the decision "represents a visual demonstration of our leadership position in this priority market, as well as Canopy Growth's growing strength within the international medical cannabis industry."

In an interview with Benzinga's Nina Zdinjak, Rozalowsky called cannabis "a must-win industry." Being a CPG expert, she joined the Canopy team in 2020 as the company's vice president of marketing.

"Since then, my role has been …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.